propafenone hydrochloride tablet film coated
cardinal health - propafenone hydrochloride (unii: 33xch0hocd) (propafenone - unii:68iqx3t69u) - propafenone hydrochloride 150 mg
propafenone hydrochloride tablet film coated
mylan institutional inc. - propafenone hydrochloride (unii: 33xch0hocd) (propafenone - unii:68iqx3t69u) - propafenone hydrochloride 150 mg
naproxen sodium- naproxen sodium tablet
remedyrepack inc. - naproxen sodium (unii: 9tn87s3a3c) (naproxen - unii:57y76r9atq) - naproxen sodium 550 mg - naproxen naproxen tablets and naproxen sodium tablets are indicated for: the relief of the signs and symptoms of: - rheumatoid arthritis - osteoarthritis - ankylosing spondylitis - polyarticular juvenile idiopathic arthritis naproxen tablets, and naproxen sodium tablets are contraindicated in the following patients: - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to naproxen or any components of the drug product [ see warnings and precautions ( 5.7, 5.9) ] - history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids have been reported in such patients [ see warnings and precautions ( 5.7, 5.8) ] - in the setting of coronary artery bypass graft (cabg) surgery [ see warnings and precautions ( 5.1) ] risk summary use of nsaids, including naproxen tablets, or naproxen sodium tablets, during the third trimester of pregnancy increases the risk of premature closure of the fetal du
naproxen sodium- naproxen sodium tablet
pd-rx pharmaceuticals, inc. - naproxen sodium (unii: 9tn87s3a3c) (naproxen - unii:57y76r9atq) - naproxen sodium 275 mg - naproxen naproxen tablets and naproxen sodium tablets are indicated for: the relief of the signs and symptoms of: - rheumatoid arthritis - osteoarthritis - ankylosing spondylitis - polyarticular juvenile idiopathic arthritis naproxen tablets, and naproxen sodium tablets are contraindicated in the following patients: - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to naproxen or any components of the drug product [ see warnings and precautions ( 5.7, 5.9) ] - history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids have been reported in such patients [ see warnings and precautions ( 5.7, 5.8) ] - in the setting of coronary artery bypass graft (cabg) surgery [ see warnings and precautions ( 5.1) ] risk summary use of nsaids, including naproxen tablets, or naproxen sodium tablets, during the third trimester of pregnancy increases the risk of premature closure of the fetal du
sodium chloride 0.9% solution for injection 2ml ampoules
hameln pharmaceuticals ltd - sodium chloride - solution for injection - 9mg/1ml
sodium chloride 0.9% solution for injection 5ml ampoules
hameln pharmaceuticals ltd - sodium chloride - solution for injection - 9mg/1ml
sodium chloride 0.9% solution for injection 10ml ampoules
hameln pharmaceuticals ltd - sodium chloride - solution for injection - 9mg/1ml
sodium chloride 0.9% solution for injection 100ml vials
hameln pharmaceuticals ltd - sodium chloride - solution for injection - 9mg/1ml
clenpiq- sodium picosulfate, magnesium oxide, and anhydrous citric acid liquid
ferring pharmaceuticals inc. - sodium picosulfate (unii: lr57574hn8) (deacetylbisacodyl - unii:r09078e41y), magnesium oxide (unii: 3a3u0gi71g) (magnesium cation - unii:t6v3lhy838), anhydrous citric acid (unii: xf417d3psl) (anhydrous citric acid - unii:xf417d3psl) - sodium picosulfate 10 mg in 160 ml - clenpiq is indicated for cleansing of the colon as a preparation for colonoscopy in adults and pediatric patients 9 years of age and older. clenpiq is contraindicated in the following conditions: - patients with severe renal impairment (creatinine clearance less than 30 ml/minute), which may result in accumulation of magnesium [see warnings and precautions (5.3)]. - gastrointestinal obstruction or ileus [see warnings and precautions (5.6)]. - bowel perforation [see warnings and precautions (5.6)]. - toxic colitis or toxic megacolon. - gastric retention. - hypersensitivity to any of the ingredients in clenpiq [see adverse reactions (6.2)]. risk summary there are no data with clenpiq use in pregnant women to determine a drug-associated risk of adverse developmental outcomes. in animal reproduction studies, no adverse developmental effects were observed in pregnant rats when sodium picosulfate, magnesium oxide, and anhydrous citric acid were administered orally at doses 1.2 times the recommended human dose based
propafenone hydrochloride capsule, extended release
american health packaging - propafenone hydrochloride (unii: 33xch0hocd) (propafenone - unii:68iqx3t69u) - propafenone hcl extended release capsules, usp are indicated to prolong the time to recurrence of symptomatic atrial fibrillation (af) in patients with episodic (most likely paroxysmal or persistent) af who do not have structural heart disease. usage considerations: - the use of propafenone er capsules in patients with permanent af or in patients exclusively with atrial flutter or paroxysmal supraventricular tachycardia (psvt) has not been evaluated. do not use propafenone er capsules to control ventricular rate during af. - some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. concomitant treatment with drugs that increase the functional atrioventricular (av) nodal refractory period is recommended. - the effect of propafenone on mortality has not been determined [see boxed warning ]. propafenone er capsules are contraindicated in the following circumstances: - heart failure - cardiogenic shock - sinoatrial, atrioventricular